Cullinan Therapeutics, INC Schedule 13G passive stakes

State Street Corporation has disclosed beneficial ownership of approximately 6% of Cullinan Therapeutics Inc.'s common stock as of June 30, 2026.

Biotechnology Value Fund and affiliates report a 9.99% beneficial ownership stake in Cullinan Therapeutics, Inc. following recent share conversions.

The Vanguard Group has reported a 0% beneficial ownership in Cullinan Therapeutics Inc. following an internal realignment.

Kynam Capital Management, LP, along with its general partner and managing member, has reported a beneficial ownership of 5.27% in Cullinan Therapeutics, Inc. as of December 31, 2025.

The Vanguard Group reported a 5.58% beneficial ownership stake in Cullinan Therapeutics Inc. common stock as of December 31, 2025.

Citadel and its affiliates, including Kenneth Griffin, have disclosed a combined beneficial ownership of 3.4% in Cullinan Therapeutics, Inc.

Lynx1 Capital Management LP and Weston Nichols reported a 9.8% beneficial ownership stake in Cullinan Therapeutics, Inc. as of September 30, 2025.

Deerfield Mgmt and affiliated entities have filed an amended Schedule 13G, reporting a reduction in their beneficial ownership of Cullinan Therapeutics, Inc. common stock to 4.95%.

The Vanguard Group has filed an amended Schedule 13G, reporting a 4.98% beneficial ownership stake in Cullinan Therapeutics Inc. as of September 30, 2025.

Lynx1 Capital Management LP and Weston Nichols reported a 14.5% beneficial ownership stake in Cullinan Therapeutics, Inc. common stock.

Lynx1 Capital Management LP and Weston Nichols have reported a 7.5% beneficial ownership stake in Cullinan Therapeutics, Inc., holding 4,400,842 shares of common stock.

Kenneth Griffin and Citadel entities report a combined beneficial ownership of 5.1% in Cullinan Therapeutics, Inc. common stock.